GeoVax Labs, Inc. (NASDAQ:GOVX) Given Average Recommendation of “Buy” by Analysts

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) have earned an average rating of “Buy” from the seven research firms that are currently covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $14.20.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $18.00 target price on shares of GeoVax Labs in a research note on Friday, March 28th.

GeoVax Labs Price Performance

GOVX opened at $1.04 on Thursday. The firm has a market capitalization of $14.39 million, a price-to-earnings ratio of -0.18 and a beta of 3.70. GeoVax Labs has a one year low of $0.88 and a one year high of $11.18. The business has a 50 day simple moving average of $1.47 and a two-hundred day simple moving average of $2.01.

GeoVax Labs (NASDAQ:GOVX) last announced its earnings results on Thursday, March 27th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.49. The business had revenue of $3.00 million for the quarter, compared to the consensus estimate of $2.38 million. As a group, sell-side analysts expect that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Trading of GeoVax Labs

A number of hedge funds have recently modified their holdings of GOVX. Geode Capital Management LLC lifted its position in GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after acquiring an additional 33,440 shares during the period. Citadel Advisors LLC bought a new position in shares of GeoVax Labs during the fourth quarter valued at approximately $104,000. Virtu Financial LLC purchased a new position in shares of GeoVax Labs during the third quarter valued at approximately $97,000. Finally, Northern Trust Corp bought a new stake in shares of GeoVax Labs in the 4th quarter worth approximately $29,000. Institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.